ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. - Wikidata - awgldk - TriplyDB

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

http://www.wikidata.org/entity/Q33601653

about

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges Targeting cancer with kinase inhibitors Membrane domain formation-a key factor for targeted intracellular drug delivery Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1.Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Endogenous retroviral promoter exaptation in human cancer The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family Twenty years of anti-HER2 therapy-associated cardiotoxicity A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3 Protein redox chemistry: post-translational cysteine modifications that regulate signal transduction and drug pharmacology Pseudokinases: update on their functions and evaluation as new drug targets.The heterogeneous landscape of ALK negative ALCL.Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs Against Leishmania major.Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells Estrogen receptor-α, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer.Clinical impact of tumour biology in the management of gastroesophageal cancer High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.EGFR-directed antibodies increase the risk of severe infection in cancer patients.A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells Personalized biochemistry and biophysics.The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment EGFR inhibits DNA mismatch repair Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.A structural perspective on the regulation of the epidermal growth factor receptor.Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer.Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer.Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.Insulin growth factor 1 like receptor (IGF-1R).

P2860

Q26751473-2C9A4E63-5514-4F84-9DB4-E0216CCEB9CF Q26771727-86836ECA-E7B2-4090-94FF-8995C283020D Q26862516-4D7D83FF-90CF-463C-BE11-4DEDEDE5817D Q26865765-66FB1078-87FB-4F91-9B8E-C28C6DC733E9 Q26998461-B736CFEA-2CA1-4F9F-9491-73A5E18E1A92 Q27349131-950079A1-DB2B-4C05-8E80-D176FD5C0711 Q27853108-4145FB7B-2993-4273-B89C-F8441B9FC96C Q27853122-929E9456-E26D-4FC3-806D-0C83FD50B5B5 Q28067477-F607C2D8-7DE4-48D8-8D90-B9E08A0DF63D Q28073335-0F1A82DA-3F36-4C28-AADE-DAC643CBB608 Q28079391-C2862B26-48FC-47F5-9F55-2CA40FC9AF26 Q28543105-4D13F908-B34C-467C-AB7B-99C3C8D64270 Q28551145-D6948758-F76C-4A10-A3AF-3FBEE0AB82D3 Q28596492-A0E5175B-C129-4FD5-9E22-5432C261DA84 Q28910204-23E16306-B7C7-4427-9EDF-713A5DA61507 Q30368044-44573267-673F-4664-BB06-9B7EB409DF1F Q30397636-4C60FA5F-5C82-4600-B46C-C047E6E6C12D Q33567012-82DD1CE9-BCBC-4807-BA35-6B8F7338480B Q33608593-7A3B85DB-FA1E-4B73-8039-C365A3732827 Q33797941-6F2CE253-9896-4750-802B-E6E1DCB647F2 Q33814199-FDFB6C25-F6AF-4813-9982-EF466BEF5803 Q33822560-E14E1250-049E-4246-9F34-01740107CBB4 Q33829859-9759AB0C-F12E-4127-8A2A-439276C5C1A9 Q33848950-12A4E516-4925-4A97-8450-F8179CD4EEEB Q33922534-DDBC9254-4593-4BBE-B2D9-C25063BE0AEA Q34436470-D28162F4-E555-49ED-97F0-DE8E5F8D812F Q35107670-6B50C9E4-93D6-47AE-B593-1150BC8323B2 Q35274443-D42ECC72-2083-4636-B46C-F567C06EB74F Q35558034-25FDD6D5-80C6-41A9-BDBC-BF7233B87CA8 Q35580748-B2ABD551-5AEC-435C-89B3-4970C64ED4E1 Q35590165-C928B820-75B1-47EC-9B45-E4D860C1FCB3 Q35663687-E2C473FA-7D1D-4760-8C0D-B51806D78FD7 Q35674768-21A7D87B-2B20-4D1B-9BF2-603B6700AC6F Q35764163-4416C5CC-A133-4BFE-ABF7-FA6517D0269C Q35829723-4D4C18BA-1392-4C19-AB91-1A834741A968 Q35895967-3E369822-E971-4E67-B82E-CDCEEAD64526 Q35917462-1D2E05B0-4822-402F-B6BD-5F6F061DE6E4 Q35987349-94B36334-0FE9-4E81-9953-C302EA00CBBF Q36103790-E08146F4-9547-40E7-A1E1-2C8A5CA2E886 Q36157136-A9A56673-4A3E-4824-9F31-317D88BCF98C

P2860

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

http://www.wikidata.org/entity/Q33601653

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@ast

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@en

type

label

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@ast

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@en

prefLabel

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@ast

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@en

P1433

Q33601653-ADAFF731-48AD-4D3A-9487-048591E7AE30

P1476

Q33601653-2840F5DC-5347-4FA2-B3A6-7244CA1DC9BA

P2093

Q33601653-2247A7C0-DDB3-441E-A6AF-622BDF26DC5A

Q33601653-BCC5C43C-538A-4E87-8D9A-D6EEBA13EE69

P2860

Q33601653-00820316-DF83-4AFD-8CD2-5EDC3B6029D7

Q33601653-010B6416-9D52-47B6-9722-6159B4ED9D0F

Q33601653-01930832-1974-416C-A5F0-3FAD5F8D103D

Q33601653-02A828F2-FEEA-4D74-BF94-0EEC5AF5B70E

Q33601653-02BC54BD-6A3E-431B-A3C8-8D9C522FDCE0

Q33601653-06DD353B-6653-4DA0-8474-4C06B1FC679D

Q33601653-0888961B-BA2B-4F6C-9A5D-47011FCE4E95

Q33601653-098E9E74-87E9-4688-BC30-A78519F21349

Q33601653-0B7726C5-4514-441D-B5BD-9FB3C32062D7

Q33601653-0BB1DAE9-FFDF-439F-81C6-EBF143527FD2

P304

Q33601653-9F209FFA-27D9-406E-A772-0BEFCDB247EA

P31

Q33601653-4991CAAE-7FF5-40F9-AA7A-430F175AEE4E

P356

Q33601653-B66CF419-EE86-4389-ABF2-14F4A9937409

P433

Q33601653-CF4E2BCB-B3F8-4FFB-BA5A-907CC8E15649

P478

Q33601653-3FC97651-CCFA-435B-895F-249F70BD4C1E

P577

Q33601653-4343CE25-CAB6-409A-AD34-340C694CE605

P5875

Q33601653-28383D52-F5F4-4DD7-B3B0-FAE6889BC60F

P698

Q33601653-31C35E68-6F7A-4EC1-8EB6-337008864B84

P932

Q33601653-6F4DCA84-1AD9-4A56-BA72-0205AAF4BA62

P356

J.CCR.2014.02.025

P1433

P1476

ERBB receptors: from oncogene ...... ism-based cancer therapeutics.

@en

P2093

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic ERBB3 mutations in human cancers

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

P304

282-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2014.02.025

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260996359

http://www.w3.org/2001/XMLSchema#string

P698

24651011

http://www.w3.org/2001/XMLSchema#string

P932

4018830

http://www.w3.org/2001/XMLSchema#string